SCHEMBL16399529

SCHEMBL16399529

N#Cc1[nH]nnc1-c1cc(Cl)cc(/C=C/c2ccc(F)cc2)c1

nearest known ligand 0.36

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ AHR P35869 3/20 0.36
▸ CYP17A1 P05093 2/20 0.35
▸ PTGS1 P23219 2/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ GRM5 P41594 1/20 0.33
▸ NFE2L2 Q16236 1/20 0.33
▸ CYP21A2 P08686 1/20 0.32
▸ CYP11B1 P15538 1/20 0.32
▸ TP53 P04637 1/20 0.32
▸ MAPT P10636 1/20 0.32
▸ NQO2 P16083 1/20 0.31
▸ ALOX5 P09917 1/20 0.31
▸ PTGS2 P35354 1/20 0.31
▸ IP6K1 Q92551 1/20 0.31
▸ IP6K3 Q96PC2 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16399531 1.00 AHR (0.36) AHRCYP17A1PTGS1CYP1A2GRM5
SCHEMBL18004514 0.91 AHR (0.45) AHRCYP17A1PTGS1CYP1A2CYP21A2
SCHEMBL18004502 0.90 CYP17A1 (0.31) CYP17A1CYP21A2CYP11B1
SCHEMBL18004462 0.88 POLB (0.33) AHRCYP17A1
SCHEMBL18004459 0.87 NFE2L2 (0.40) PTGS1NFE2L2NQO2PTGS2
SCHEMBL18004355 0.87 AHR (0.52) AHRCYP17A1PTGS1NQO2
SCHEMBL16399488 0.86 NFE2L2 (0.39) CYP17A1PTGS1NFE2L2CYP21A2CYP11B1
SCHEMBL16399489 0.86 NFE2L2 (0.39) CYP17A1PTGS1NFE2L2CYP21A2CYP11B1
SCHEMBL18004540 0.85 ERBB2 (0.42) NFE2L2TP53MAPTALOX5
SCHEMBL18004460 0.85 ADORA1 (0.35) AHRCYP17A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4570313-A2 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2025-06-18 — — EP claimed
EP-4219477-A1 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2023-08-02 — — EP claimed
US-10626095-B2 Cyanotriazole compounds OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2020-04-21 — — US claimed
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2016-08-11 — — US claimed
EP-4570313-A2 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2025-06-18 — — EP disclosed
EP-4219477-A1 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2023-08-02 — — EP disclosed
EP-4219477-A1 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2023-08-02 — — EP disclosed
US-10626095-B2 Cyanotriazole compounds OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2020-04-21 — — US disclosed
US-10626095-B2 Cyanotriazole compounds OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2020-04-21 — — US disclosed
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2016-08-11 — — US disclosed
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2016-08-11 — — US disclosed
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2016-08-11 — — US disclosed
EP-3022199-A1 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2016-05-25 — — EP disclosed
WO-2015008872-A1 CYANOTRIAZOLE COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2015-01-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10626095-B2 Cyanotriazole compounds CS, PC, ACAT1 AHR 3515/4885CYP17A1 434/4885PTGS1 2094/4885
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS CS, PC, ACAT1 AHR 3515/4885CYP17A1 434/4885PTGS1 2094/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback